Key Segments:
By Product
-
Semaglutide (Rybelsus/Oral Wegovy)
-
Orforglipron
-
Other Pipeline Candidates
By Indication
-
Type 2 Diabetes Management
-
Obesity & Weight Management
-
Others
By Formulation Technology
-
SNAC-Based Peptide Formulation
-
Non-Peptide Small Molecule Formulation
-
Others
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
Saudi Arabia
-
UAE
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company's specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The Oral GLP-1 Therapeutics Market is expected to grow at a CAGR of approximately 35.0% from 2026 to 2035, based on triangulated secondary research estimates.
The Oral GLP-1 Therapeutics Market was valued at approximately USD 6.81 Billion in 2025, based on triangulation across multiple independent research sources.
The major growth factor is rising global prevalence of type 2 diabetes and obesity, strong patient preference for needle-free treatment, and the landmark FDA approval of oral Wegovy for chronic weight management.
The Semaglutide (Rybelsus/Oral Wegovy) segment dominated the Oral GLP-1 Therapeutics Market by product, representing the largest share of revenue in 2025.
North America dominated the Oral GLP-1 Therapeutics Market in 2025, holding an estimated 62.0% share of total global market revenue.